Yu Ping Fan

7381737, Jun 3, 2008

Sep 29, 2005

11/238427

Albert J. DelMonte - Edison NJ, US
T. G. Murali Dhar - Newtown PA, US
Yu Fan - Highland Park NJ, US
Jack Z. Gougoutas - Princeton NJ, US
Mary F. Malley - Lawrenceville NJ, US
Douglas D. McLeod - Kingston NJ, US
Robert E. Waltermire - Hillsborough NJ, US
Chenkou Wei - Princeton Junction NJ, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 31/4188
C07D 235/00

514389, 5483014

A process is provided for preparing spiro-hydantoin compounds of the formula II.

20080269499, Oct 30, 2008

May 30, 2008

12/130915

Albert J. DelMonte - Edison NJ, US
Yu Fan - Highland Park NJ, US
Jack Z. Gougoutas - Princeton NJ, US
Mary F. Malley - Lawrenceville NJ, US
Douglas D. McLeod - Kingston NJ, US
Robert E. Waltermire - Hillsborough NJ, US
Chenkou Wei - Princeton Junction NJ, US

BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ

C07D 487/10

5483014

A process is provided for preparing spiro-hydantoin compounds of the formula IIwherein Z is N or CR; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; Ais a linker, G′ is a linker; Q is a linker; and R, R, R, and Rare defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

20220177482, Jun 9, 2022

Feb 22, 2022

17/677312

- Princeton NJ, US
Collin Chan - New York NY, US
Joerg Deerberg - Columbus NJ, US
Nathan R. Domagalski - Niantic CT, US
Martin D. Eastgate - Titusville NJ, US
Yu Fan - Highland Park NJ, US
Michael David Bengt Fenster - New York NY, US
Robert V. Forest - Hillsborough NJ, US
Rebecca A. Green - Metuchen NJ, US
Matthew R. Hickey - Yardley PA, US
Nathaniel David Kopp - Newtown PA, US
Thomas E. La Cruz - Flemington NJ, US
Kathleen Lauser - Minneapolis MN, US
Hong Geun Lee - Seoul, KR
David K. Leahy - Hightstown NJ, US
Helen Y. Luo - San Francisco CA, US
Thomas M. Razler - Yardley PA, US
Scott A. Savage - Yardley PA, US
Chris Sfouggatakis - Staten Island NY, US
Maxime C.D. Soumeillant - Princeton NJ, US
Serge Zaretsky - Fords NJ, US
Bin Zheng - Kendall Park NJ, US
Ye Zhu - Singapore, SG

C07D 487/04

The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide,

20200223852, Jul 16, 2020

Jul 19, 2018

16/631915

- Princeton NJ, US
Collin Chan - New York NY, US
Joerg Deerberg - Columbus NJ, US
Nathan R. Domagalski - Niantic CT, US
Martin D. Eastgate - Titusville NJ, US
Yu Fan - Highland Park NJ, US
Michael David Bengt Fenster - New York NY, US
Robert V. Forest - Hillsborough NJ, US
Rebecca A. Green - Metuchen NJ, US
Matthew R. Hickey - Yardley PA, US
Nathaniel David Kopp - Newtown PA, US
Thomas E. La Cruz - Flemington NJ, US
Kathleen Lauser - Minneapolis MN, US
Hong Geun Lee - Seoul, KR
David K. Leahy - Hightstown NJ, US
Helen Y. Luo - San Francisco CA, US
Thomas M. Razler - Yardley PA, US
Scott A. Savage - Yardley PA, US
Chris Sfouggatakis - Staten Island NY, US
Maxime C.D. Soumeillant - Princeton NJ, US
Serge Zaretsky - Fords NJ, US
Bin Zheng - Kendall Park NJ, US
Ye Zhu - Singapore, SG

C07D 487/04

The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolodin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.